[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356219-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356219-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","m6a-targeted-cancer-therapy-molecular-targets-inhibitors-and-nanodelivery-strategies","m6A-Targeted Cancer Therapy - Molecular Targets, Inhibitors, and Nanodelivery Strategies","","m6A methylation is a widespread, dynamic RNA post-transcriptional modification that regulates stability, translation, and degradation, shaping gene expression programs relevant to cancer. By modulating oncogenic and tumor-suppressive transcripts, m6A dysregulation supports tumor initiation and progression. Recent m6A-targeted therapy combines m6A inhibitors and regulator-directed RNA strategies with nanocarriers to enhance stability, pharmacokinetics, tumor accumulation, and selectivity, while addressing remaining delivery and specificity barriers for clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/m6a-targeted-cancer-therapy-molecular-targets-inhibitors-and-nanodelivery-strategies/356219/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/m6a-targeted-cancer-therapy-molecular-targets-inhibitors-and-nanodelivery-strategies/356219.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the role of m6A methylation in cancer-related RNA regulation?","Question",{"text":63,"@type":64},"m6A is a widespread RNA modification that affects stability, translation, and degradation. Dysregulation of m6A regulators can change the expression and stability of oncogenic and tumor-suppressive transcripts, influencing tumor initiation and progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do m6A-targeted therapies typically act at the molecular level?",{"text":68,"@type":64},"m6A-targeted agents primarily target m6A “writers” and “erasers” to reduce or increase intracellular m6A levels. Specific inhibitors (e.g., FTO-related approaches) have shown anticancer effects in preclinical models.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is nanodelivery integrated into m6A-targeted cancer therapy?",{"text":72,"@type":64},"Nanodelivery can improve drug stability, pharmacokinetic properties, tumor accumulation, and therapeutic selectivity. The review highlights integration with lipid nanoparticles, polymeric nanoparticles, and extracellular vesicle-based systems to strengthen therapeutic performance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356219,1790990133,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nm6A-Targeted Cancer Therapy: Molecular  \nTargets, Inhibitors, and Nanodelivery Strategies  \nChenyu Li 1 , 2 , *, Yuan Guo2 , *, Wenjun Jiang 1 , *, Wei Xie 3 , Yao Yao 1  \n1Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China; 2GCP Office, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, People’s Republic of China; 3Digital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Wei Xie, Digital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, People’s Republic of China, [Email xiew@sumhs.edu.cn](Email xiew@sumhs.edu.cn); Yao Yao, Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China, [Email yaoyaolab@163.com](Email yaoyaolab@163.com)  \n\n| Abstract: m6A methylation modification, a widespread RNA post-transcriptional modification in eukaryotes, has been shown to playa crucial role in various biological processes, including gene expression regulation, cell proliferation and differentiation. By regulating RNA stability, translation, and degradation, m6A can influence the expression of oncogenic and tumor-suppressive transcripts and thereby contribute to cancer initiation and progression. In recent years, m6A-targeted therapy has emerged as a promising approach in cancer treatment, particularly with the development of m6A inhibitors and the integration of nano-delivery technologies, which have demonstrated significant therapeutic potential. This review summarizes recent advances in m6A-targeted cancer therapy, with emphasis on small-molecule inhibitors and RNA-based strategies targeting m6A regulators, and highlights their integration with nanocarriers, including lipid nanoparticles, polymeric nanoparticles, and extracellular vesicle-based systems, to improve drug stability, pharmacokinetic properties, tumor accumulation, and therapeutic selectivity. This integrated perspective highlights the emerging role of nanodelivery in advancing m6A-targeted cancer therapy and provides a framework for understanding its therapeutic potential. Despite these advances and promising preclinical evidence, the clinical translation of m6A-targeted therapies remains limited, with challenges related to drug specificity, delivery optimization, and the complexity of m6A regulatory networks. Finally, the article envisions future research directions, emphasizing the integration of interdisciplinary technologies, and predicts the broad prospects of m6A-targeted therapy in precision cancer treatment.\u003Cbr>Keywords: m6A, inhibitor, nano-delivery, targeted therapy |\n| --- |\n| Introduction\u003Cbr>The m6A methylation modification is a widespread form of RNA modification in eukaryotes, and is the most abundant internal modification of mRNA.1 This modification plays a crucial role in a variety of RNA-related biological processes, including RNA transcription, 3’ end processing, nuclear export, translational regulation, and RNA stabilization.2 Compared with many other RNA modifications, the dynamic and reversible nature of m6A, together with its broad effects on RNA stability, translation, and degradation, provides multiple opportunities for therapeutic intervention in cancer.3 The regulatory role of m6A methylation is essential in gene expression control, with significant implications in tumor initiation and progression.4,5 Importantly, dysregulation of m6A regulators can alter the expression and stability of oncogenic and tumor-suppressive transcripts, highlighting the therapeutic potential of targeting m6A in cancer. Recent st","cbCaiaub7AEEhXQz","https://ap.wps.com/l/cbCaiaub7AEEhXQz","pdf",10697401,25,"English","# Abstract\n# Introduction\n## m6A methylation and its roles in RNA biology\n## Therapeutic opportunities from dysregulated m6A regulators","[{\"question\":\"What is the role of m6A methylation in cancer-related RNA regulation?\",\"answer\":\"m6A is a widespread RNA modification that affects stability, translation, and degradation. Dysregulation of m6A regulators can change the expression and stability of oncogenic and tumor-suppressive transcripts, influencing tumor initiation and progression.\"},{\"question\":\"How do m6A-targeted therapies typically act at the molecular level?\",\"answer\":\"m6A-targeted agents primarily target m6A “writers” and “erasers” to reduce or increase intracellular m6A levels. Specific inhibitors (e.g., FTO-related approaches) have shown anticancer effects in preclinical models.\"},{\"question\":\"Why is nanodelivery integrated into m6A-targeted cancer therapy?\",\"answer\":\"Nanodelivery can improve drug stability, pharmacokinetic properties, tumor accumulation, and therapeutic selectivity. The review highlights integration with lipid nanoparticles, polymeric nanoparticles, and extracellular vesicle-based systems to strengthen therapeutic performance.\"}]","m6A-Targeted Cancer Therapy - Molecular Targets, Inhibitors, and Nanodelivery Strategies | PDF",1790124127,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b03e3a4bf8a75f80f0a3639f8f7a3f19.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14f66c8c02f797265da820a1d9c8ab73.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dd9e8c6963805977e71819b43bb2495.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c96d8b37878acb18658c6414ed751a37.webp",980,1268]